The three groups are doing the evaluation in combination with Syndax’sentinostat, an investigational oral small molecule that targets immune regulatory cells in patients with heavily pre-treated and recurrent ovarian cancer.
This agreement between the alliance and Syndax to study the combination of these two investigational agents in ovarian cancer is considered unique since Syndax will be responsible for conducting the Phase Ib/II clinical trial in ovarian cancer.
Dr. Mace Rothenberg, Senior Vice President of Clinical Development and Medical Affairs and Chief Medical Officer for Pfizer Oncology said the collaboration with Syndax adds a new dimension to their quest to pursue combination immuno-oncology regimens based on compelling preclinical rationale and the potential to generate clinical results.
Also, Dr. Luciano Rossetti, Head of Global Research & Development of the biopharma business of Merck said, “Combination therapy is the next frontier in immuno-oncology and a key strategy for the alliance.”
On his part, Dr. Briggs W. Morrison, Syndax’s Chief Executive Officer expressed delight in working with the alliance to explore the potential benefits of entinostat in combination with avelumab for ovarian cancer patients.